Venus Concept Inc.
VERONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for VERO. That does not mean none is planned.
Get an email about VERO's next catalysts
Track Venus Concept (VERO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
How VERO's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CSE-1034 (Ceftriaxone + Sulbactam + EDTA) | Phase 3 | Urinary Tract Infection Complicated | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Venus Concept Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Venus Concept Inc.'s (VERO) pipeline across Phase 3. Its lead program is CSE-1034 (Ceftriaxone + Sulbactam + EDTA) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Venus Concept Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Venus Concept Inc. (VERO) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track VERO biotech catalysts?β
Add VERO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Venus Concept Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
